# NCT04185883 (NCT04185883)

> Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04185883
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
- Interventions: Sotorasib; Trametinib; RMC-4630; Afatinib; Pembrolizumab; Panitumumab; Carboplatin, pemetrexed, docetaxel, paclitaxel; Atezolizumab; Palbociclib; MVASI® (bevacizumab-awwb); TNO155; IV Chemotherapy (Regimen 1); IV Chemotherapy (Regimen 2); BI 1701963; AMG 404; Everolimus
- Enrollment: 610
- Primary outcome: Number of Participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
- Primary outcome: Number of Participants with Treatment-related Adverse Events
- Primary outcome: Number of Participants with Clinically Significant Changes in Vital Signs
- Primary outcome: Number of Participants with Clinically Significant Changes in ECG Measurements
- Primary outcome: Number of Participants with Clinically Significant Changes in Laboratory Test Values

## Commentary we found

- X threads: 27
- Podcasts: 11
- YouTube: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04185883

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04185883", "email": "<work email>"}; the inbox owner confirms by the emailed link.